ABVC Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
ABVC Biopharma Inc is not a strong buy for a beginner, long-term investor with $50,000-$100,000 available for investment. The technical indicators are mixed, with bearish moving averages and neutral RSI, while the MACD shows slight positive momentum. Options data suggests neutral sentiment with no significant volume activity. The lack of recent news or major catalysts, combined with no recent congress trading data, further diminishes the appeal. Despite strong revenue growth in the latest quarter, the company remains unprofitable, which may not align with a beginner investor's long-term goals. Therefore, it is recommended to hold off on buying this stock at the moment.
The MACD histogram is slightly positive at 0.0122, indicating weak upward momentum. RSI is neutral at 42.331, suggesting no clear overbought or oversold conditions. However, the moving averages are bearish, with SMA_200 > SMA_20 > SMA_5, indicating a downward trend. Key support and resistance levels are Pivot: 1.419, R1: 1.608, S1: 1.23, R2: 1.725, S2: 1.114.
Revenue increased by 104.47% YoY in Q3 2025, showing strong top-line growth. Net income improved significantly YoY, up 215.76%, and EPS improved by 66.67%.
No recent news, congress trading data, or major catalysts to drive the stock price. Bearish moving averages and neutral insider/hedge fund sentiment further weigh on the stock.
In Q3 2025, revenue increased by 104.47% YoY to $795,950. Net income improved by 215.76% YoY but remains negative at -$1,246,513. EPS improved by 66.67% YoY to -0.05. Gross margin increased slightly to 100%.
No recent analyst ratings or price target changes available.
